Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases

Infection trains the host for microbiota-enhanced resistance to pathogens

(2021) Apollo Stacy et al.   CELL

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

(2021) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer

(2021) Lulu Sun et al.   Nature Reviews Gastroenterology & Hepatology

Hyocholic acid species as novel biomarkers for metabolic disorders

(2021) Xiaojiao Zheng et al.   Nature Communications

TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation

(2021) Yong Shi et al.   Frontiers in Immunology

Ceramides and other sphingolipids as drivers of cardiovascular disease

(2021) Ran Hee Choi et al.   Nature Reviews Cardiology

Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice

(2021) Lili Ding et al.   Acta Pharmaceutica Sinica B

The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities

(2021) Marta Mazzetti et al.   Journal of Clinical Medicine

Glycoursodeoxycholic Acid Ameliorates Diet-induced Metabolic Disorders with Inhibiting Endoplasmic Reticulum Stress

(2021) Lele Cheng et al.   CLINICAL SCIENCE

Circulating Bile Acid Profiles: A Need for Further Examination

(2021) Li Qi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Understanding the physiological functions of the host xenobiotic-sensing nuclear receptors PXR and CAR on the gut microbiome using genetically modified mice

(2021) Mallory Little et al.   Acta Pharmaceutica Sinica B

Bile acid homeostasis in female mice deficient in Cyp7a1 and Cyp27a1

(2021) Daniel Rizzolo et al.   Acta Pharmaceutica Sinica B

Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake

(2020) Victoria Meslier et al.   GUT

Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis

(2020) Rohit Loomba et al.   HEPATOLOGY

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

Long-Term Changes in Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk

(2020) Yoriko Heianza et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study

(2020) Armin Mooranian et al.   Scientific Reports

The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids

(2020) Sarah Ducastel et al.   Scientific Reports

The microbiome modulating activity of bile acids

(2020) Yuan Tian et al.   Gut Microbes

Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism

(2020) Preeti Pathak et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

FXR-mediated inhibition of autophagy contributes to FA-induced TG accumulation and accordingly reduces FA-induced lipotoxicity

(2020) Kun Wu et al.   Cell Communication and Signaling

Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells

(2020) Clarissa Campbell et al.   NATURE

Improving prevention strategies for cardiometabolic disease

(2020) Naveed Sattar et al.   NATURE MEDICINE

Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges

(2020) Ming Li et al.   PHARMACOLOGY & THERAPEUTICS

Trimethylamine N-Oxide levels are associated with NASH in obese subjects with type 2 diabetes

(2020) Paola León-Mimila et al.   DIABETES & METABOLISM

Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)

(2020) Stefano Fiorucci et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A metabolic pathway for bile acid dehydroxylation by the gut microbiome

(2020) Masanori Funabashi et al.   NATURE

An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis

(2020) Yifeng Wang et al.   Nature Communications

TGR5/Cathepsin E signaling regulates macrophage innate immune activation in liver ischemia and reperfusion injury

(2020) Haoming Zhou et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A Unique Population of Regulatory T Cells in Heart Potentiates Cardiac Protection from Myocardial Infarction

(2020) Ni Xia et al.   CIRCULATION

Systemic Immunometabolism: Challenges and Opportunities

(2020) Alexander Lercher et al.   IMMUNITY

Vitamin D3 receptor polymorphisms regulate T cells and T cell-dependent inflammatory diseases

(2020) Gonzalo Fernandez Lahore et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters

(2020) Ying Wang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

(2020) Takaomi Kessoku et al.   BMJ Open

Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy

(2020) Guofeng Ji et al.   Acta Pharmaceutica Sinica B

Apaf-1 Pyroptosome Senses Mitochondrial Permeability Transition

(2020) Wanfeng Xu et al.   Cell Metabolism

Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism

(2020) Xiaojiao Zheng et al.   Cell Metabolism

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

(2020) Rohit Loomba et al.   HEPATOLOGY

DCA-TGR5 signaling activation alleviates inflammatory response and improves cardiac function in myocardial infarction

(2020) Jiaxing Wang et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice

(2019) Patricia D. Finn et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome

(2019) Ziwei Song et al.   Microbiome

Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters

(2019) Lulu Sun et al.   Acta Pharmaceutica Sinica B

Trimethylamine N ‐Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease

(2019) Xuying Tan et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Emerging roles of bile acids in mucosal immunity and inflammation

(2019) Mei Lan Chen et al.   Mucosal Immunology

Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation

(2019) Adriana Carino et al.   Nutrients

Comparison of diets enriched in stearic, oleic, and palmitic acids on inflammation, immune response, cardiometabolic risk factors, and fecal bile acid concentrations in mildly hypercholesterolemic postmenopausal women—randomized crossover trial

(2019) Huicui Meng et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

(2019) Upendra Kaul et al.   Cardiovascular Diabetology

Obeticholic acid may increase the risk of gallstone formation in susceptible patients

(2019) Samer Al-Dury et al.   JOURNAL OF HEPATOLOGY

Farnesoid X Receptor alters adipose tissue architecture in mice and limits storage capacity leading to metabolic derangements

(2019) Tim van Zutphen et al.   JOURNAL OF LIPID RESEARCH

Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice

(2019) Bingning Dong et al.   HEPATOLOGY

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

(2019) Paul J. Pockros et al.   LIVER INTERNATIONAL

Shikonin attenuates hyperhomocysteinemia-induced CD4+ T cell inflammatory activation and atherosclerosis in ApoE−/− mice by metabolic suppression

(2019) Si-lin Lü et al.   ACTA PHARMACOLOGICA SINICA

Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development

(2019) Enchen Zhou et al.   CARDIOVASCULAR RESEARCH

Bile acid metabolites control TH17 and Treg cell differentiation

(2019) Saiyu Hang et al.   NATURE

Activation of TGR5 Partially Alleviates High Glucose-Induced Cardiomyocyte Injury by Inhibition of Inflammatory Responses and Oxidative Stress

(2019) Li Deng et al.   Oxidative Medicine and Cellular Longevity

The protective effect of lithocholic acid on the intestinal epithelial barrier is mediated by the vitamin D receptor via a SIRT1/Nrf2 and NF-κB dependent mechanism in Caco-2 cells

(2019) Baiyu Yao et al.   TOXICOLOGY LETTERS

Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota

(2019) Danfeng Chen et al.   CANCER LETTERS

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial

(2019) Marcos Pedrosa et al.   Contemporary Clinical Trials

Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis

(2019) Mohammad Shadab Siddiqui et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis

(2019) Xinyang Song et al.   NATURE

Bile salt metabolism is not the only factor contributing to Clostridioides (Clostridium) difficile disease severity in the murine model of disease

(2019) Caitlin A. Jukes et al.   Gut Microbes

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis

(2018) B. Hameed et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

INT-777, a bile acid receptor agonist, extenuates pancreatic acinar cells necrosis in a mouse model of acute pancreatitis

(2018) Baiqiang Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

An Integrated View of Immunometabolism

(2018) Yun Sok Lee et al.   CELL

Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming

(2018) Anette Christ et al.   CELL

Evidence that TLR4 Is Not a Receptor for Saturated Fatty Acids but Mediates Lipid-Induced Inflammation by Reprogramming Macrophage Metabolism

(2018) Graeme I. Lancaster et al.   Cell Metabolism

An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers

(2018) Amani Al-Khaifi et al.   GASTROENTEROLOGY

Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism

(2018) Preeti Pathak et al.   HEPATOLOGY

The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice

(2018) Takashi Sasaki et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects

(2018) A. Ahmad et al.   JOURNAL OF HEPATOLOGY

The Nuclear Bile Acid Receptor FXR is a PKA- and FOXA2-Sensitive Activator of Fasting Hepatic Gluconeogenesis

(2018) Maheul Ploton et al.   JOURNAL OF HEPATOLOGY

Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation

(2018) Shinobu Miyazaki-Anzai et al.   JOURNAL OF LIPID RESEARCH

FGF-19 agonism for NASH: a short study of a long disease

(2018) Michael Charlton   LANCET

Role of Bile Acids in Metabolic Control

(2018) Antonio Molinaro et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue

(2018) Laura A. Velazquez-Villegas et al.   Nature Communications

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis

(2018) Ying-Bin Hu et al.   Drug Design Development and Therapy

Deoxycholic Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Exacerbates DSS-Induced Colitis through Promoting Cathepsin B Release

(2018) Shengnan Zhao et al.   Journal of Immunology Research

The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism

(2018) Sarah Just et al.   Microbiome

A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters

(2018) Mao-xu Ge et al.   ACTA PHARMACOLOGICA SINICA

TGR5 Activation Promotes Stimulus-Secretion Coupling of Pancreatic β-Cells via a PKA-Dependent Pathway

(2018) Jonas Maczewsky et al.   DIABETES

Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis

(2018) Adriana Carino et al.   FASEB JOURNAL

Small Heterodimer Partner and Fibroblast Growth Factor 19 Inhibit Expression of NPC1L1 in Mouse Intestine and Cholesterol Absorption

(2018) Young-Chae Kim et al.   GASTROENTEROLOGY

Microbial impact on cholesterol and bile acid metabolism: current status and future prospects

(2018) Aicha Kriaa et al.   JOURNAL OF LIPID RESEARCH

Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism

(2018) Lin Ding et al.   Lipids in Health and Disease

Gut microbiota and intestinal FXR mediate the clinical benefits of metformin

(2018) Lulu Sun et al.   NATURE MEDICINE

Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome

(2018) Maja Ðanić et al.   Frontiers in Pharmacology

Bile acids and their effects on diabetes

(2018) Cynthia Rajani et al.   Frontiers of Medicine

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice

(2017) Jan Freark de Boer et al.   GASTROENTEROLOGY

Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease

(2017) Oscar Chávez-Talavera et al.   GASTROENTEROLOGY

Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD

(2017) Na Jiao et al.   GUT

Monocyte-Macrophages and T Cells in Atherosclerosis

(2017) Ira Tabas et al.   IMMUNITY

Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials

(2017) Morten Hansen et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

(2017) Auvro R. Mridha et al.   JOURNAL OF HEPATOLOGY

The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis

(2017) Michele Biagioli et al.   JOURNAL OF IMMUNOLOGY

Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III

(2017) M. Ghosh Laskar et al.   JOURNAL OF INTERNAL MEDICINE

Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents

(2017) Masamichi Watanabe et al.   JOURNAL OF LIPID RESEARCH

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

(2017) David C. Tully et al.   JOURNAL OF MEDICINAL CHEMISTRY

Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation

(2017) Lili Sheng et al.   JOURNAL OF PATHOLOGY

Inflammation, metaflammation and immunometabolic disorders

(2017) Gökhan S. Hotamisligil   NATURE

Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor

(2017) Thijs W. H. Pols et al.   PLoS One

Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to TLR4 accessory protein MD2

(2017) Yi Wang et al.   Nature Communications

Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions

(2017) Paul M. Ryan et al.   Diabetology & Metabolic Syndrome

Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice

(2017) Adriana Carino et al.   Scientific Reports

Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin

(2016) Gerald F. Watts et al.   ATHEROSCLEROSIS

Ursodeoxycholic acid impairs atherogenesis and promotes plaque regression by cholesterol crystal dissolution in mice

(2016) Niklas Bode et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism

(2016) Annika Wahlström et al.   Cell Metabolism

Adaptive Response of T and B Cells in Atherosclerosis

(2016) Daniel F.J. Ketelhuth et al.   CIRCULATION RESEARCH

Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers

(2016) R. Pencek et al.   DIABETES OBESITY & METABOLISM

Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism

(2016) Thibaut Duparc et al.   GUT

Microbiota-induced obesity requires farnesoid X receptor

(2016) Ava Parséus et al.   GUT

Prostaglandin E2promotes hepatic bile acid synthesis by an E prostanoid receptor 3-mediated hepatocyte nuclear receptor 4α/cholesterol 7α-hydroxylase pathway in mice

(2016) Shuai Yan et al.   HEPATOLOGY

Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice

(2016) Yang Xu et al.   HEPATOLOGY

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

(2016) Juan P. Arab et al.   HEPATOLOGY

Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome

(2016) Chuansheng Guo et al.   IMMUNITY

Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis

(2016) Divya P. Kumar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deoxycholic Acid Triggers NLRP3 Inflammasome Activation and Aggravates DSS-Induced Colitis in Mice

(2016) Shengnan Zhao et al.   Frontiers in Immunology

The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity

(2015) Evie P.M. Broeders et al.   Cell Metabolism

Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque

(2015) Abed Janoudi et al.   EUROPEAN HEART JOURNAL

The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease

(2015) Kazuya Okushin et al.   JOURNAL OF GASTROENTEROLOGY

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity

(2015) Michaela Mueller et al.   JOURNAL OF HEPATOLOGY

24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis

(2015) Martina Sombetzki et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting Endoplasmic Reticulum (ER) Stress Induced by Disturbed Flow

(2015)   MOLECULES AND CELLS

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

(2015) Sungsoon Fang et al.   NATURE MEDICINE

Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders

(2015) Stefano Fiorucci et al.   TRENDS IN MOLECULAR MEDICINE

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

(2015) Changtao Jiang et al.   Nature Communications

A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity

(2014) D.-H. Kim et al.   EMBO JOURNAL

TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation

(2014) Alessia Perino et al.   JOURNAL OF CLINICAL INVESTIGATION

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

(2014) Changtao Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

G-Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5) Agonists Reduce the Production of Proinflammatory Cytokines and Stabilize the Alternative Macrophage Phenotype

(2014) Klemens Högenauer et al.   JOURNAL OF MEDICINAL CHEMISTRY

Beyond intestinal soap—bile acids in metabolic control

(2014) Folkert Kuipers et al.   Nature Reviews Endocrinology

Pleiotropic Roles of Bile Acids in Metabolism

(2013) Thomas Q. de Aguiar Vallim et al.   Cell Metabolism

Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist

(2013) Sama I. Sayin et al.   Cell Metabolism

Trimethylamine-N-Oxide, a Metabolite Associated with Atherosclerosis, Exhibits Complex Genetic and Dietary Regulation

(2013) Brian J. Bennett et al.   Cell Metabolism

Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice

(2013) Diana M. Shih et al.   FASEB JOURNAL

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis

(2013) Lars P. Bechmann et al.   HEPATOLOGY

Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease

(2013) Rachel H. McMahan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Vitamin D Controls Murine and Human Plasmacytoid Dendritic Cell Function

(2013) Nina Karthaus et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis

(2013) Robert A Koeth et al.   NATURE MEDICINE

Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice

(2012) Kouichi Miura et al.   HEPATOLOGY

Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway

(2012) Riko Ichikawa et al.   IMMUNOLOGY

Ursodeoxycholic Acid in Patients With Chronic Heart Failure

(2012) Stephan von Haehling et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading

(2011) Thijs W.H. Pols et al.   Cell Metabolism

The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in mice

(2011) Yan-Dong Wang et al.   HEPATOLOGY

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

(2011) Zeneng Wang et al.   NATURE

The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity

(2010) Rinke Stienstra et al.   Cell Metabolism

Transgenic expression of cholesterol 7α-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice

(2010) Tiangang Li et al.   HEPATOLOGY

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

(2010) Peter Duewell et al.   NATURE